Abstract: A volatile composition having: (i) greater than 30% of a scented hydrophobic material by weight of the volatile composition, wherein the scented hydrophobic material comprises one or more volatile compounds; and (ii) greater than 20% of a regulating scent intensity (RIS) composition by weight of the volatile composition. The RIS composition has at least two of: a first regulating scent intensity component (RIS component) having a high average vapor pressure (VP); a second RIS component having a medium average VP; and a third RIS component having a low average VP; The average VP of each of said one or more volatile compounds is lower than at least one of the high, medium and low average VPs of the first, second and third RIS components at the same temperature.

Abstract: Described herein are perfuming compositions and perfumed consumer products including, as perfuming ingredients, cyclopentanone compounds of formula in a form of any one of its stereoisomers or a mixture thereof, where n represents 1.

Abstract: A liquid laundry composition having from about 6% to about 50%, by weight of the laundry composition, of a surfactant component. The surfactant component having from about 0.5% to about 30%, by weight of the laundry composition, of an HLAS surfactant selected from alkyl benzene sulfonic acids, alkali metal or amine salts of C10-16 alkyl benzene sulfonic acids, wherein the HLAS surfactant comprises greater than 50% C12.

Abstract: A water-soluble unit dose article containing a water-soluble film and a liquid laundry detergent composition having a first anionic surfactant, and a method of making the water-soluble unit dose article.

Abstract: A detergent composition having a) from about 10% to about 60%, by weight of the composition, of a surfactant system wherein the surfactant system includes: i) at least 35%, by weight of the surfactant system, of nonionic surfactant and ii) from 5% to about 20%, by weight of the surfactant system, of amine oxide.

Abstract: Liquid multipurpose alkaline compositions for use as pre-sprays to beneficially remove polymerized soils, de-stain, remove hard water deposits and/or otherwise assist in general cleaning of difficult soils are provided. The multipurpose alkaline compositions include at least one non-hydroxide alkaline source, at least one surfactant, a chelant and a solvent system. The multipurpose alkaline compositions can be PPE free compositions. Methods of using the multipurpose alkaline compositions as pre-treatments, soaks and/or application in machine and manual warewash are also provided. Methods for using the multipurpose alkaline compositions for removing tea stains, coffee stains, hard water scale/deposits, polymerized oils, carbonized soils, fats, oils, and cosmetics are further provided.

Abstract: A fuser fluid composition is disclosed, including a non-fluorinated functional silicone fluid, and a non-fluorinated non-functional silicone fluid, where the non-fluorinated functional silicone fluid is present in the fuser fluid composition in an amount of from about 1 wt % to about 30 wt % based on a total weight of the fuser fluid composition, and the non-fluorinated non-functional silicone fluid is present in the fuser fluid composition in an amount of from about 50 wt % to about 99 wt % based on a total weight of the fuser fluid composition. The non-fluorinated functional silicone fluid may include an amine-functional group. A cleaning web and a fusing subsystem for a printing system may include a material impregnated with the fuser fluid composition.

Abstract: A device for infusing smoke flavor into beverages includes a board, at least one recessed smoking well, an infuser and tubing. The board has a board thickness. The at least one recessed smoking well is recessed into a top surface of the board. The infuser is housed inside of the board. The infuser is configured to create smoke. The infuser includes a fan configured to direct the smoke created. The tubing connects the infuser to the recessed smoking well. Wherein, once lit, the infuser is configured to direct smoke it creates through the tubing and into the recessed smoking well. Whereby, the device is configured to infuse smoke flavor into a glass containing the beverage positioned in the recessed smoking well by directing smoke created from the infuser through the tubing and into the recessed smoking well.

Abstract: The present disclosure provides cell culture chambers for use in automated cell engineering systems, and in particular, cell culture chambers that include improved cell-contacting surfaces. Improved cell-contacting surfaces can include a surface coating that promotes cell growth, adherence, differentiation, maintenance of phenotype, and/or improves transduction; a cell-contacting surface comprising a non-porous, gas-permeable material; as well as other modifications to the cell-contacting surfaces. Cassettes comprising the cell culture chambers are also provided.

Abstract: The present disclosure generally relates to an alignment mount for electrode device used to measure transepithelial/transendothelial electrical resistance (TEER) for cell culture models of endothelial and epithelial monolayers. The TEER electrode alignment mount includes a base having a top wall, a bottom wall and a sidewall shaped to fit within a culture tray chamber. An extension arm projects from a top wall of the base. A pair of through apertures are formed in the base on opposing sides of the arm to receive first and second electrodes therethrough, respectively. An optional adjustable sliding sleeve for changing the height of the arm can be selectively coupled to the extension arm.

Abstract: The methods and systems described herein provide a cell culture platform with an array of tissue modeling environments and dynamic control of fluid flow. The cell culture platform includes an array of wells that are fluidically coupled by microchannel structures. The dynamically controlled flow of fluid interacts with cells grown within the microchannels.

Abstract: Disclosed is a device for angling a multi-well plate during shaking on a typical low speed laboratory incubator-shaker to facilitate cell growth. An assembly with a holder for a deep-well multi-well plate to attach it to a base has an adjustable-angle joint. The base is attached to a conventional incubator shaker tray via screws or a sticky pad. The adjustable-angle joint allows maintaining the desired angle of the plate, even at full shaking speed.

Abstract: A portable apparatus and method for transport and incubation of a medical sample in a blood culture flask includes a sealable container having a thermally insulated compartment for receiving the blood culture flask and a heater for heating the medical sample to a temperature suitable for pre-culturing of the sample. An agitator is provided for agitating the sample in the blood culture flask.

Abstract: Aspects of the present invention relate to a networked cell culture incubator and to methods for operating such an incubator. In one aspect, the cell culture incubator includes a network interface for communicating with a source of parameter data utilized successfully by other incubators. The incubator receives appropriate parameter data and conducts the incubation process as prescribed by the parameter data so as to provide an improved environment for cell culture growth. The incubator may share its own parameter data with the data source for use by other incubators. The incubator and data source may share other forms of data as well.

Abstract: Nitrogen in a form suitable for feeding a population of microbes in a bioreactor is produced by reacting nitrogen gas and hydrogen gas to form ammonia plus an unreacted gas stream under conditions favorable to having little unreacted nitrogen gas in the unreacted gas stream. The ammonia, or a compound derived from the ammonia is fed to the microbes and the unreacted gas stream is optionally fed back into the reaction, or fed into the bioreactor. Oxygen can be produced, such as by electrolysis, and also provided to the microbes. Hydrogen from the electrolysis can be added to the hydrogen being reacted with nitrogen gas, and/or can be added to the bioreactor. Where nitrogen gas is produced from air separation, the residual gases can be another source of oxygen.

Abstract: This invention concerns an integrated microfluidic system that utilizes microfluidic chip technology to receive a patient sample including cells, expand the cells, reprogram the expanded cells and then store the reprogrammed cells in a microfluidic chip. These microfluidic chips with stored reprogrammed cells may then be used in scenarios of genetic differentiation into specific cell types. Overall this system and workflow is suitable as a hospital based device that will allow the generation of iPSCs from every patient for downstream diagnostic or therapeutic use.

Abstract: The present disclosure provides for engineered microorganisms and methods of making and using same. The engineered microorganisms as described herein can have a surface display and can be useful as therapeutic agents (e.g., sponges) and biosensors.

Abstract: Systems and methods are provided for classifying microbial cells according to morphological features of microcolonies. A dark-field objective is employed to acquire a dark-field image of a microcolony during a microcolony growth phase that is characterized by phenotypic expression of microcolony morphological features which evolve with time and are differentiated among classes of microbial cell types. The dark-field image is processed to classify the microcolony according to two or more microbial cell types, such as Gram status and/or speciation. The dark-field objective may have a numerical aperture selected to facilitate the imaging of microcolony morphological features, residing, for example, between 0.15 and 0.35. A set of dark-field images of a microcolony may be collected during the microcolony growth phase and processed to classify the microcolony. Classification may be performed according to a temporal ordering of the dark-field images, for example, using a recurrent neural network.

Abstract: A nucleic acid synthesis device and a nucleic acid purification device, uses thereof, and a nucleic acid synthesis method and a nucleic acid purification method. The nucleic acid synthesis device includes a solid support, and the solid support includes a controlled pore glass (CPG), the CPG is an unmodified and bare CPG, a surface of the CPG has a hydroxyl group, and the hydroxyl group is attachable, though a covalent bond, to a phosphoramidite-protected nucleotide monomer or multimer for synthesis of nucleic acid. The nucleic acid synthesis device of the present disclosure can be used for not only synthesis of an oligonucleotide primer, but also for purification of enzymatic digestion and PCR product by using the oligonucleotide primer immobilized on the CPG, and has advantages of simple structure, small volume, light weight, high efficiency, low costs, and diversified functions.

Abstract: This invention relates to the storage on a solid matrix of genetic material, in particular DNA that has been purified prior to the application to the solid matrix. More specifically, the invention relates to a solid matrix for the storage of purified DNA, which matrix has been treated with a solution comprising plant polysaccharide inulin. One advantage of the invention is that an increased amount of DNA can be stored in the solid matrix of the present invention.

Abstract: Oligonucleotide primers and methods of use in producing sequencing libraries are provided according to aspects of the present disclosure which include, from 5? to 3?, a homopolymer-hybridizing region, and an anchor region comprising 5?-(?)nNm-3?, wherein the homopolymer-hybridizing region is a contiguous sequence of 5 to 20 elements, wherein the elements are nucleotides or Tm increasing nucleotide analogs, wherein at least 4 of the elements are Tm increasing nucleotide analogs, wherein the homopolymer-hybridizing region hybridizes to a complementary homopolymer tract of a target nucleic acid, wherein the complementary homopolymer tract comprises a contiguous sequence of complementary elements, wherein X is any nucleotide or nucleotide analog with the proviso that ? is not a nucleotide or nucleotide analog complementary to a complementary element of the complementary homopolymer tract, and wherein N is any nucleotide or nucleotide analog.

Abstract: The present application provides materials and methods for treating a patient with autosomal dominant RP, both ex vivo and in vivo; materials and methods for editing a RHO gene in a human cell; and materials and methods for editing a P23H mutation in a RHO gene in a human cell. In addition, the present application provides one or more gRNAs or sgRNAs for editing a RHO gene; one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene. The present application provides a therapeutic for treating a patient with autosomal dominant RP. The present application provides a kit for treating a patient with autosomal dominant RP. In addition, the present application provides a self-inactivating CRISPR-Cas system.

Abstract: DNA molecules for making a circular RNA are provided. The DNA molecule may include elements operably connected and arranged, from a 5? to 3? direction, in the following order: (a) an intron fragment that includes a full-length intron; (b) an E2 fragment which includes a downstream exon of the full-length intron; and (c) an E1 fragment which includes an upstream exon of the full-length intron. 3? end of the E1 fragment is configured to produce a hydroxyl group in an in vitro transcription reaction; the hydroxyl group is capable of initiating splicing in a one-step transesterification reaction at a splice site between RNA fragments transcribed from the intron fragment and the E2 fragment in a linear RNA that is produced from the DNA molecule in the in vitro transcription reaction, such that the linear RNA is configured to self-circularize to produce the circular RNA.

Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The antisense strand of the dsRNA molecule comprises at least one thermally destabilizing nucleotide occurring at a seed region; the dsRNA comprises at least four 2?-fluoro modifications, and the sense strand of the dsRNA molecule comprises ligand, wherein the ligand is an ASGPR ligand. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.

Abstract: Disclosed herein are Advanced RNA Targeting (ARNATAR) dsRNA compounds targeting angiotensinogen (AGT). Such compounds are useful in methods for reducing expression of AGT and for therapeutically treating RAAS associated diseases, disorders and/or conditions, or symptoms thereof in a subject.

Abstract: The present disclosure relates to compositions of matter and assay methods used to detect one or more target nucleic acids of interest in a sample. The compositions and methods allow one to control reaction kinetics of the cascade assay by two orders of magnitude via molecular design of one of the reaction components; further, varying molecular design also allows for quantification of target nucleic acids of interest over a large range of concentrations or discriminating between extremely low copy numbers of target nucleic acids of interest.

Abstract: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).

Abstract: The present invention identified BCL2 gene inhibitor based on long non-coding RNA, the sequence of SEQ ID NO: 1; Which could interact with BCL2 and inhibit its expression effectively, thereby inhibiting the growth and metastasis of tumor, and benefiting patients in the process of tumor treatment.

Abstract: The present disclosure concerns recombinant microbial host cell having, in glycolytic conditions, increased glycerol importing activity glycerol as well as, in high osmotic conditions, a decreased NAD-dependent glycerol-3-phosphate dehydrogenase (GPD) activity. The recombinant microbial host cell is particularly useful for the fermentation of sugarcane- or molasses-based medium for the production of ethanol.

Abstract: The present invention relates generally to genes and polypeptides which have utility in glycosylating quillaic acid in host cells, including enzymes capable of successive glycosylation at the C-3 position of quillaic acid. The invention further relates to systems, methods and products employing the same.

Abstract: This invention relates to the expression a DA1 protein with a mutation that disrupts or inactivates the LIM domain or the LIM-like domain within cells of a plant. This may increase the yield or enhance a yield-related trait of the plant. Methods, plants and plant cells are provide.

Abstract: Methods and materials for modulating low light and/or shade tolerance, and red light specific responses in plants are disclosed. For example, nucleic acids encoding low light and/or SD+EODFR-tolerance polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also disclosed are plants having increased low light and/or SD+EODFR tolerance. In addition, methods and materials involved in increasing UV-B tolerance in plants and methods and materials involved in modulating biomass levels in plants are provided.

Abstract: The present invention relates to a modified gene that provides resistance to Cucurbit Yellow Stunting Disorder virus (CYSDV) when present in a plant of the Cucurbitaceae family. The invention further relates to progeny, seed, and fruit of the plant that is resistant against CYSDV. The invention also relates to propagation material suitable for producing the plant that is resistant to CYSDV. Additionally, the invention relates to methods for producing, identifying, and selecting a plant of the Cucurbitaceae family having resistance against CYSDV.

Abstract: Provided herein are gene therapy methods for the treatment of mucopolysaccharidosis type IVA (MPS IVA) involving the use of recombinant adeno-associated viruses (rAAVs) to deliver human N-acetylgalactosamine-6-sulfate sulfatase (hGALNS) to the bone of a human subject diagnosed with MPS IVA. Also provided herein are rAAVs that can be used in the gene therapy methods and methods of making such rAAVs.

Abstract: The compositions and methods are described for generating an immune response to an antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens as a fusion product with a viral glycoprotein and matrix protein for generating a protective immune response to a subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat diseases.

Abstract: The present invention relates to a lysosomal protein composition comprising a plurality of lysosomal proteins that are potentially diversely glycosylated according to a glycosylation pattern, wherein said glycosylation pattern has at least 45% paucimannosidic N-glycans; a method of manufacturing the lysosomal protein composition in a bryophyte plant or cell, and medical and non-medical uses of the lysosomal protein composition. E.g. the lysosomal protein can be ?-Galactosidase for the treatment of Fabry Disease or ?-Glucoceramidase for the treatment of Gaucher's Disease. The unique glycosylation results in improved therapeutic efficacy—surprisingly even without mannose-6-phosphate that is common for CHO cell produced lysosomal proteins.

Abstract: The present invention relates to compositions and methods for mass production of pluripotent stem cells derived from non-human-animal, particularly in a form of aggregates suitable for a variety of uses, particularly to mass production of aggregates of bovine-derived pluripotent stem cells for use in cell grown meat cultures and in production of cell based meat products.

Abstract: The present invention provides a method for preparing 3D brain organoids, comprising the following steps: neurospheres obtained by the RONA method are dissociated into single cells by accutase, plated on a cell culture plate after being counted, cultured in medium A until day 7; neurospheres are cultured in medium B until day 25˜35, and then they are encapsulated by Matrigel; neurospheres are further cultured in media B until day 55˜65, and then they are encapsulated by Matrigel for the second time and cultured continually afterwards. The present invention also provides a medium for culturing 3D brain organoids. The present invention begins with highly purified neurospheres obtained by the RONA method, and neuronal stem cells can be controlled and cultured to achieve true 3D brain organoids with uniform size and structure by this relatively simple method.

Abstract: The present invention relates to a method of producing expandable cultured brain cells. The brain cells are neurotrophic factor (NTF) positive. The expandable cultured brain cells are obtained by culturing a biopsy obtained from the cortical and/or subcortical brain region of a living subject. The biopsies can be obtained during neurosurgical procedures such as deep brain stimulation. The expandable cultured brain cells of the present invention are useful for the treatment of neurological diseases and other medical conditions.

Abstract: The present invention relates to a method for inducing the differentiation of corneal epithelial cells from pluripotent stem cells. More specifically, the present invention relates to a method for autonomously differentiating pluripotent stem cells, such as human iPS cells, into ectodermal cell lineage in a serum-free medium without using feeder cells and inducing the differentiation of the resultant ocular surface ectodermal lineage cells into corneal epithelial cells.

Abstract: A bioreactor device includes a solid substrate having a first face and a second face. The solid substrate at least partially defines a perfusion channel, a plurality of chambers, a fluidic inlet, and a fluidic outlet. A first sheet disposed over the first face and a second sheet disposed over the second face. Characteristically, the combination of the solid substrate, the first sheet and the second sheet define the perfusion channel and each chamber of the plurality of chambers. The plurality of chambers are arranged in rows of chambers in which adjacent chambers are positioned at opposite side of the perfusion channel. The perfusion channel extends from the fluidic inlet and the fluidic outlet having a serpentine path along each row of chambers with each chamber being in fluid communication with the perfusion channel.

Abstract: It is described a composite hydrogel containing egg white and alginate (EWA) polymers, and a method of producing same, wherein the alginate is cross-linked using frozen calcium chloride disks, creating a scaffold for cells comprising a slow-rate ions diffusion through the matrix, ensuring a homogenous crosslink and smooth surface.

Abstract: The present invention relates to methods that are based on expression of integrin alpha10 and integrin alpha11 on chondrocytes, used for determining purity, quality, degree of chondrocytic identity, chondrocytic potency, and/or degree of chondrocytic phenotype of a composition comprising chondrocytes, as well as for isolating and enriching a population of high quality chondrocytes and controlling culturing and expanding of high quality chondrocytes. The present invention relates also to composition comprising chondrocytes.

Abstract: Long awaited is a human liver-like three-dimensional construct that makes it possible to carry out evaluation of human-specific toxicity and the like accurately and in a simple manner. The present invention provides a human liver-like three-dimensional construct comprising a heterospheroid, in which human hepatic cells and other human-derived cells which are not human hepatic cells are aggregated. This human liver-like three-dimensional construct is characterized in that the other human-derived cells are at least one selected from human hepatic stellate cells and the like, and the other human-derived cell to the human hepatic cell count ratio is at least 0.01 but less than 1.

Abstract: Cell culture mediums for generating organoids, including tumour organoids. Specifically, such mediums comprise: a cell culture medium; an antioxidant; a serum free supplement; an insulin receptor agonist; a glucocorticoid; and an FGFR agonist. Other aspects involve methods of generating tumour organoids from tumours. Such methods can comprise generating pancreatic progenitor organoids from pluripotent stem cells, pancreatic lineage committed progenitors.

Abstract: Disclosed herein are methods and compositions of decellularized preterm placental tissue. Compositions comprise decellularized regenerative tissue derived from animal placentas that are harvested preterm, i.e., before the completion of the normal duration of gestation. Preterm placental tissue may contain a high level of growth factors and other beneficial components that aid in tissue regeneration and healing.

Abstract: Provided are methods and compositions for inducing the reprogramming of a non-pluripotent to an iPSC having desirable properties using a vector system providing transient and temporal expression of transgenes that are short-lived. Also provided are reprogramming cells and iPSC populations or clonal cell lines using the provided reprogramming methods and compositions. Further provided are genome-engineered iPSCs and derived cells redifferentiated therefrom to comprise targeted editing involving insertions and deletions in one or more selected genomic loci.

Abstract: Described herein are methods for providing an in vitro intestinal model system, e.g., using primary cells instead of cell lines and/or cancerous cells.

Abstract: A method of non-covalently loading a plant picornavirus is described. The method includes contacting a plant picornavirus in solution with a molar excess of a cargo molecule to load the plant picornavirus with the cargo molecule, and then purifying the loaded plant picornavirus. Examples of cargo molecules include imaging agents, antitumor agents, and antiviral agents. Loaded plant picornaviruses prepared in this manner can be used to delivering cargo molecule to cells.

Abstract: The objective of the present invention is to provide a novel bacteriophage useful for treating bacterial endophthalmitis and a therapeutic agent for bacterial endophthalmitis comprising the novel bacteriophage. The therapeutic agent for bacterial endophthalmitis according to the present invention is characterized in comprising 1 or more bacteriophages selected from the group essentially consisting of Myoviridae Spounavirinae phiEF7H (accession number: NITE BP-02886), Myoviridae Spounavirinae phiEF19G (accession number: NITE BP-02887), Myoviridae Spounavirinae phiEF14H1 (accession number: NITE BP-02888), and mutants thereof.